Daiwa Securities Group
BLCM

Daiwa Securities Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Daiwa Securities Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-18
Closed -$1K – 1199
2018
Q3 		$1K Hold
18
– – ﹤0.01% 1151
2018
Q2 		$1K Hold
18
– – ﹤0.01% 1172
2018
Q1 		$1K Buy
+18
New +$1.36K ﹤0.01% 1159

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Daiwa Securities Group's BLCM Position: Q4 2018 in Review

Daiwa Securities Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 18 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in BLCM in Q1 2018 and held it in 3 quarters. The position peaked at $1K in Q3 2018. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

  • Daiwa Securities Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Daiwa Securities Group sold 18 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1K.
  • Daiwa Securities Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • Daiwa Securities Group's Bellicum Pharmaceuticals, Inc. position peaked at $1K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on Daiwa Securities Group's 13F filing for Q4 2018, filed 5 Feb 2019.